RARG and acute promyelocytic leukemia: In one case, azacitidine was used for maintenance therapy after transplantation, and a patient with AML and NUP98-RARG gene fusion presenting as APL was treated with induction and consolidation chemotherapy using venetoclax in combination with chemotherapy, and then achieved CR followed by haploidentical hematopoietic stem cell transplantation.